GuideAI Health Corp. has received final approval to list its common shares on Cboe Canada, with trading expected to commence at the market open on June 29, 2026. The shares will trade under the ticker symbol GDAI, assigned ISIN CA40173G1019 and CUSIP 40173G101. This listing allows investors to trade shares through standard investment channels, including discount brokerages and full-service dealers.

The company operates at the intersection of artificial intelligence and cardiovascular health, providing a platform that analyzes routine CT scans to identify peripheral vascular disease. By surfacing disease earlier, GuideAI aims to improve patient outcomes and assist hospitals and radiology groups in delivering comprehensive vascular care.

"Going public represents an important milestone for GuideAI as we scale our platform and expand access to advanced diagnostic technology," said Raj Shah, Chief Executive Officer of GuideAI Health Corp. He emphasized the company's mission to improve outcomes for patients, clinicians, and shareholders.

Cboe Canada CEO Joacim Wiklander welcomed the company, noting that its innovative approach represents the type of high-growth enterprise the exchange seeks to support. The listing provides GuideAI with a robust and internationally recognized platform to enhance investor trust and liquidity.

Key Listing Details

The forward-looking statements regarding the listing and business plans are based on management's assumptions and are subject to risks, including potential delays in final approval or changes in market conditions. Cboe Canada has not reviewed or approved the contents of this release.

GuideAI Health Corp. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for VascularAssist Occlusion Triage (VAOT), an artificial intelligence software designed to support the prioritization and triage of vascular occlusion in the lower extremities. The clearance, granted on June 22, 2026, marks a significant step for the company in integrating AI into radiology workflows to improve patient outcomes for those at risk of limb-threatening disease.

VAOT is a Class II, AI-based Software as a Medical Device (SaMD) operating as a Computer-Aided Triage and Notification device (CADt). The software assists radiologists in identifying and characterizing significant peripheral vascular disease (PVD), a leading contributor to acute and chronic limb ischemia. By flagging suspected vascular occlusion for prioritized review within existing imaging workflows, VAOT aims to help clinical teams reduce time to diagnosis and intervention.

In clinical performance testing supporting the clearance, VAOT demonstrated strong accuracy in identifying disease at the patient level. The software achieved 95% patient-level sensitivity in 2D analysis and 94% patient-level sensitivity in 3D analysis for identifying Peripheral Artery Disease-positive patients, defined as patients with at least one lesion at 50% or greater stenosis.

"Receiving FDA 510(k) clearance for VAOT is a defining milestone for GuideAI and for the patients we ultimately aim to serve," said Raj Shah, MD, MBA, Chief Executive Officer of GuideAI Health. "Peripheral vascular disease is too often missed or detected late, with devastating consequences. VAOT brings AI-powered triage directly into the radiology workflow, helping clinicians identify vascular disease sooner so patients can be directed to the right care faster."

Clinical Performance Metrics

The following table summarizes the clinical performance metrics achieved by VAOT during testing:

GuideAI Health Corp. is a healthcare technology company using artificial intelligence to enable the early detection of vascular disease and support more precise treatment decisions. Its platform analyzes routine CT scans to identify peripheral vascular disease and other vascular conditions that are frequently missed or under-reporting, generating structured, actionable reports for radiologists and treating clinicians.